<DOC>
	<DOCNO>NCT00085358</DOCNO>
	<brief_summary>This phase I trial study side effect best dose intraperitoneal infusion carboplatin give together intravenous infusion either docetaxel paclitaxel follow intraperitoneal paclitaxel treat patient stage II , stage III , stage IV ovarian epithelial , fallopian tube , primary peritoneal cavity carcinoma ( cancer ) . Drugs use chemotherapy , carboplatin , docetaxel , paclitaxel , work different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell</brief_summary>
	<brief_title>Carboplatin Paclitaxel With Without Bevacizumab Compared Docetaxel , Carboplatin , Paclitaxel Treating Patients With Stage II , Stage III , Stage IV Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cavity Carcinoma ( Cancer )</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) intraperitoneal ( IP ) carboplatin give combination IV paclitaxel follow IP paclitaxel patient stage III IV ovarian epithelial , fallopian tube , primary peritoneal cavity carcinoma . II . Determine MTD IP carboplatin IV docetaxel give combination IP paclitaxel patient . III . To determine feasibility combination IV paclitaxel , IP carboplatin IV bevacizumab day one follow IP paclitaxel day eight ( Part C Only ) . IV . Determine dose-limiting toxic effect complication patient treat regimen . V. Evaluate neurotoxicity regimen cycle use FACT/GOG-NTX4 assessment tool determine dose reduction patient . VI . Evaluate technique use intraperitoneal catheter placement , surgical procedure , report outcome patient . OUTLINE : This multicenter , dose-escalation study intraperitoneal ( IP ) carboplatin . Patients dose-escalation phase eligible enter feasibility phase . DOSE-ESCALATION PHASE ( PART A PART B ) : Patients receive IP carboplatin day 1 , paclitaxel IV 3 hour ( part A ) docetaxel IV 1 hour ( Part B ) day 1 , IP paclitaxel day 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . FEASIBILITY PHASE ( PART C ) : Patients receive IP carboplatin day 1 , paclitaxel IV day 1 , IP paclitaxel day 8 course 1 part A dose-escalation phase . Beginning course 2 subsequent course , patient receive IP carboplatin day 1 , IV paclitaxel day 1 , IP paclitaxel day 8 dose-escalation phase , bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm fallopian tube , ovarian epithelial , primary peritoneal carcinoma Stage IIIV disease The following epithelial cell type allow : Carcinosarcoma Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner 's tumor Adenocarcinoma otherwise specify Must undergone prior surgery ovarian peritoneal carcinoma within past 12 week Optimal ( ≤ 1 cm residual disease ) suboptimal residual disease follow initial surgery Must procedure determine diagnosis ovarian/peritoneal carcinoma appropriate tissue histologic evaluation Synchronous primary endometrial cancer prior endometrial cancer allow provide follow criterion meet : Stage ≤ IB Less 3 mm invasion without vascular lymphatic invasion No poorly differentiate subtypes ( e.g. , grade 3 , clear cell , papillary serous ) No epithelial ovarian carcinoma low malignant potential ( borderline carcinoma ) No CNS disease ( e.g. , seizure control standard medical therapy ) metastasis GOG performance status 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 INR ≤ 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin management venous thrombosis include pulmonary thromboembolus ) ( applies part C ) PTT &lt; 1.2 time upper limit normal ( applies part C ) SGOT ≤ 2.5 time normal Alkaline phosphatase ≤ 2.5 time normal Bilirubin ≤ 1.5 time normal Creatinine ≤ 1.5 time normal No active bleeding Abnormal cardiac conduction ( e.g. , bundle branch block heart block ) allow provided disease remain stable past 6 month No unstable angina myocardial infarction within past 6 month No neuropathy ( sensory motor ) &gt; CTCAE grade 1 Not pregnant nursing Fertile patient must use effective contraception least 6 month completion study therapy No septicemia , severe infection , acute hepatitis No invasive malignancy within past 5 year except nonmelanoma skin cancer localize breast cancer No circumstance would preclude study participation No history allergic reaction polysorbate 80 ( e.g. , etoposide vitamin E ) No know hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody ( applies part C ) No clinically significant proteinuria Must urine proteincreatinine ratio ( UPCR ) &lt; 1 No serious , nonhealing wound , ulcer , bone fracture ( applies part C ) At least 36 month since prior abdominal fistula gastrointestinal perforation fully recover ( part C ) No history intraabdominal abscess within past 28 day ( applies part C ) No active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel ( applies part C ) No history evidence ( upon physical examination ) CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis ( applies part C ) No history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date treatment study ( applies part C ) No significant traumatic injury within 28 day ( applies part C ) No clinically significant cardiovascular disease , include follow ( applies part C ) : Uncontrolled hypertension , define systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg Myocardial infarction unstable angina &lt; 6 month prior registration New York Heart Association ( NYHA ) Grade II great congestive heart failure Serious cardiac arrhythmia require medication CTCAE Grade 2 great peripheral vascular disease ( least brief ( &lt; 24 hr ) episodes ischemia manage nonsurgically without permanent deficit ) History CVA within past six month No clinical symptom sign gastrointestinal obstruction require parenteral hydration and/or nutrition ( applies part C ) No prior therapy antiVEGF drug , include bevacizumab ( applies part C ) No prior chemotherapy Prior adjuvant chemotherapy localize breast cancer allow provide therapy complete least 3 year registration study patient remain free recurrent metastatic disease No prior radiotherapy No prior cancer therapy would contraindicate study treatment No anticipation invasive procedure , include follow ( applies part C ) : Major surgical procedure open biopsy within 28 day prior first date bevacizumab therapy ( cycle 2 ) Major surgical procedure anticipate course study Core biopsy within 7 day prior first date bevacizumab therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>